| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $88M | ||
| $82M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Over the last 12 months, insiders at NRx Pharmaceuticals, Inc. have bought $0 and sold $0 worth of NRx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at NRx Pharmaceuticals, Inc. have bought $288,851 and sold $1.22M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 40,000 shares for transaction amount of $46,800 was made by Javitt Jonathan C (Chairman and Chief Scientist) on 2024‑12‑17.
| 2024-12-17 | Javitt Jonathan C | Chairman and Chief Scientist | 40,000 0.2543% | $1.17 | $46,800 | +62.50% | ||
| 2023-08-30 | Hurvitz Chaim | director | 70,000 0.0777% | $0.29 | $20,125 | +1.74% | ||
| 2023-08-30 | Gorovitz Aaron | director | 35,000 0.0432% | $0.32 | $11,197 | +1.74% | ||
| 2023-08-23 | Javitt Jonathan C | Chief Scientist | 100,000 0.135% | $0.33 | $33,000 | +14.44% | ||
| 2023-08-22 | Javitt Jonathan C | Chief Scientist | 200,000 0.2614% | $0.32 | $64,400 | +7.62% | ||
| 2022-12-16 | Willard Stephen H | CHIEF EXECUTIVE OFFICER | 50,000 0.0773% | $1.17 | $58,500 | -55.52% | ||
| 2022-12-16 | VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | 30,000 0.0436% | $1.10 | $33,000 | -55.52% | ||
| 2022-12-07 | Sale | Javitt Jonathan C | director | 400,000 0.4224% | $1.00 | $400,000 | -63.19% | |
| 2022-11-30 | Sale | Javitt Daniel C. | director | 8,441 0.0134% | $1.50 | $12,700 | -60.42% | |
| 2022-11-29 | Sale | Javitt Daniel C. | director | 13,730 0.0228% | $1.50 | $20,651 | -58.70% | |
| 2022-11-28 | Flynn Patrick John | director | 6,750 0.0102% | $1.25 | $8,413 | -54.32% | ||
| 2022-11-25 | VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | 16,337 0.0241% | $1.11 | $18,215 | -49.65% | ||
| 2022-11-18 | Hurvitz Chaim | director | 40,408 0.0593% | $1.10 | $44,449 | -47.89% | ||
| 2022-11-17 | Sale | Javitt Daniel C. | director | 33,018 0.0433% | $1.05 | $34,745 | -51.07% | |
| 2022-11-17 | Hurvitz Chaim | director | 171,780 0.2312% | $1.08 | $185,522 | -51.07% | ||
| 2022-11-16 | Sale | Javitt Daniel C. | director | 133,719 0.1975% | $1.02 | $136,393 | -42.86% | |
| 2022-11-16 | Hurvitz Chaim | director | 287,812 0.4126% | $0.99 | $284,934 | -42.86% | ||
| 2022-11-11 | Sale | Javitt Daniel C. | director | 49,200 0.0753% | $1.01 | $49,510 | -38.75% | |
| 2022-07-29 | Sale | Javitt Daniel C. | 784,063 1.5019% | $1.01 | $791,433 | -6.94% | ||
| 2022-06-03 | Sale | Javitt Daniel C. | 115,657 0.1594% | $0.67 | $76,947 | +0.54% |
| Javitt Daniel C. | director | 9634793 55.7385% | $17.92M | 0 | 7 | |
| Hurvitz Chaim | director | 570000 3.2975% | $1.06M | 4 | 0 | <0.0001% |
| Polar Asset Management Partners Inc. | 10 percent owner | 488036 2.8233% | $907,746.96 | 0 | 1 | |
| ACKERMAN RICHARD | President and CEO | 225000 1.3017% | $418,500.00 | 1 | 1 | +2.4% |
| Gorovitz Aaron | director | 105000 0.6074% | $195,300.00 | 1 | 0 | +1.74% |
| Javitt Jonathan C | Chairman and Chief Scientist | 84634 0.4896% | $157,419.24 | 4 | 1 | +28.39% |
| Willard Stephen H | CHIEF EXECUTIVE OFFICER | 50000 0.2893% | $93,000.00 | 1 | 0 | <0.0001% |
| VAN VOORHEES SETH | CHIEF FINANCIAL OFFICER | 46337 0.2681% | $86,186.82 | 2 | 0 | <0.0001% |
| Flynn Patrick John | director | 40209 0.2326% | $74,788.74 | 1 | 0 | <0.0001% |
| Besthof Robert | Chief Comm. & Patient Officer | 23710 0.1372% | $44,100.60 | 0 | 1 | |
| Daigneault Alessandra | General Counsel & Secretary | 0 0% | $0 | 0 | 1 |
$2,458,011 | 109 | 12.54% | $38.36M | |
$14,315,062 | 61 | -6.21% | $27.69M | |
$2,983,776 | 25 | -16.47% | $34.83M | |
$523,320 | 24 | 94.37% | $32.59M | |
$241,165 | 22 | -16.72% | $34.63M | |
$26,786,140 | 22 | -18.62% | $34.53M | |
$91,209,456 | 15 | -7.00% | $37.85M | |
NRx Pharmaceuticals, Inc. (NRXP) | $1,091,554 | 14 | -16.96% | $32.15M |
$33,809,329 | 11 | -64.88% | $26.79M | |
$131,130 | 10 | 16.11% | $31.61M | |
$70,584,874 | 10 | 3.97% | $25.33M | |
$13,595,542 | 9 | -16.74% | $26.77M | |
$232,423 | 8 | 14.22% | $30.61M | |
$8,470,804 | 6 | -13.28% | $29.35M | |
$8,997,728 | 2 | -11.16% | $34.86M | |
$100,266 | 2 | 3.17% | $28.03M | |
$150,000 | 1 | 5.48% | $26.73M | |
$4,999,995 | 1 | -67.50% | $33.61M | |
$5,512,500 | 1 | -7.91% | $34.84M |
| Increased Positions | 14 | +48.28% | 2M | +46.53% |
| Decreased Positions | 12 | -41.38% | 562,141 | -14.21% |
| New Positions | 7 | New | 556,115 | New |
| Sold Out Positions | 3 | Sold Out | 317,361 | Sold Out |
| Total Postitions | 31 | +6.9% | 5M | +32.32% |
| Anson Funds Management Lp | $5,306.00 | 6.75% | 2.03M | +420,129 | +26.18% | 2025-09-30 |
| Vanguard Group Inc | $1,402.00 | 1.78% | 534,956 | +82,781 | +18.31% | 2025-09-30 |
| Advisorshares Investments Llc | $896.00 | 1.14% | 342,136 | +78,339 | +29.7% | 2025-09-30 |
| Marshall Wace, Llp | $496.00 | 0.63% | 189,136 | +155,752 | +466.55% | 2025-09-30 |
| Geode Capital Management, Llc | $487.00 | 0.62% | 185,862 | +13,607 | +7.9% | 2025-09-30 |
| Ubs Group Ag | $400.00 | 0.51% | 152,848 | +31,240 | +25.69% | 2025-09-30 |
| Renaissance Technologies Llc | $336.00 | 0.43% | 128,175 | +128,175 | New | 2025-09-30 |
| State Street Corp | $200.00 | 0.25% | 76,284 | +25,200 | +49.33% | 2025-09-30 |
| Jane Street Group, Llc | $192.00 | 0.25% | 73,399 | +73,399 | New | 2025-09-30 |
| Blackrock, Inc. | $171.00 | 0.22% | 65,412 | +1,012 | +1.57% | 2025-09-30 |